After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Eli Lilly is reaping the benefits from its innovation in diabetes and obesity management, with therapies like Mounjaro and ...

U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that ...

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean ...

Trump aims to impose tariffs on pharmaceutical imports to boost US production, but industry fears shortages and increased ...

WeightWatchers has stood as a source of hope for millions seeking to shed pounds through community support, disciplined ...

President Trump has said major drugmakers such as Eli Lilly, Johnson & Johnson, and Pfizer should manufacture more of their ...

President Trump’s threatened tariffs could lead to higher out-of-pocket costs or insurance premiums, depending on whether ...

U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that ...

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

We recently published a list of the 10 High Growth Dividend Paying Stocks to Invest in. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other ...